STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences, Inc. - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.

Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.

The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.

Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.

The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.

For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.

News

Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy

Rhea-AI Summary
Castle Biosciences, Inc. will present new data at the ASTRO 2023 Annual Meeting demonstrating the ability of its DecisionDx®-SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART). The test significantly stratified the cohort according to risk of metastasis, with metastasis-free survival rates of 92.4%, 76.1%, and 59.4% for patients with Class 1, Class 2A, and Class 2B test results, respectively. This could guide risk-aligned treatment decisions and potentially de-intensify treatment for some patients. Abstracts will be published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
none
-
News

Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus

Rhea-AI Summary
Castle Biosciences, Inc. presents data showing clinical utility of its TissueCypher® Barrett’s Esophagus test in guiding risk-aligned upstaging of care for patients with non-dysplastic Barrett’s esophagus (NDBE) at a higher risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
News

Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will ring the Nasdaq closing bell on Sept. 27 to raise awareness of melanoma. Their DecisionDx-Melanoma test improves health outcomes for patients with melanoma. Melanoma claims nearly 20 American lives each day. Castle's test provides personalized information about a patient's risk of recurrence, metastasis, and lymph node positivity. The company will also ring the NYSE closing bell on Sept. 28 to celebrate the launch of the Texas Capital Texas Equity Index ETF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Rhea-AI Summary
Castle Biosciences' TissueCypher test outperforms standard pathology review in predicting progression to esophageal cancer in Barrett's esophagus patients with initial low-grade dysplasia diagnosis, according to a study published in Gastroenterology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
News

Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory

Rhea-AI Summary
Castle Biosciences, Inc. receives Clinical Laboratory Permit for its Pittsburgh laboratory from the New York State Department of Health, expanding its ability to impact patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
News

Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression

Rhea-AI Summary
Castle Biosciences, Inc. announces data showing IDgenetix test significantly improves remission rates for patients with depression
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
News

TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus

Rhea-AI Summary
Castle Biosciences to present data on the risk stratification performance of its TissueCypher test for Barrett's Esophagus at the 19th ISDE World Congress for Esophageal Diseases. The test identified a subset of patients with non-dysplastic Barrett's esophagus (NDBE) who had a similar risk of progression to high-grade dysplasia/esophageal adenocarcinoma as patients with low-grade dysplasia. TissueCypher also identified low-risk subsets of patients whose care could be de-escalated and managed with surveillance only. The data suggest that the use of TissueCypher could increase early detection and benefit patients at higher risk of progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
-
News

Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023

Rhea-AI Summary
Castle Biosciences to present new data on IDgenetix test at Psych Congress 2023 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News

Castle Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Castle Biosciences to present at Baird’s Global Healthcare Conference and Lake Street Best Ideas Growth Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
conferences
News

New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
none

FAQ

What is the current stock price of Castle Biosciences (CSTL)?

The current stock price of Castle Biosciences (CSTL) is $29.81 as of November 22, 2024.

What is the market cap of Castle Biosciences (CSTL)?

The market cap of Castle Biosciences (CSTL) is approximately 842.5M.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in diagnostic tests for various cancers, providing genomic information to aid in treatment decisions.

When was Castle Biosciences founded?

Castle Biosciences was founded in 2008.

What types of cancer does Castle Biosciences have tests for?

Castle Biosciences has tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma.

What are some of Castle Biosciences' notable products?

Notable products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME.

Is Castle Biosciences involved in research for new diagnostic tests?

Yes, they have active research programs in rectal cancer and soft tissue sarcoma, among others.

Where can I find more information about Castle Biosciences and its products?

You can visit their official website at www.castlebiosciences.com for more detailed information.

What is the primary mission of Castle Biosciences?

The primary mission is to provide personalized, clinically actionable genomic information to make more accurate treatment decisions.

Does Castle Biosciences collaborate with other entities?

Yes, they work closely with outstanding members of the oncology community throughout the discovery, development, and utilization of their tests.

What is Castle Biosciences' financial condition?

The company is in a robust financial condition, reflecting successful commercialization efforts and consistent revenue growth.

How does Castle Biosciences contribute to cancer care?

By providing objective and accurate diagnostic tests, Castle Biosciences helps advance cancer care and improve patient outcomes.

Stock CSTL logo
Castle Biosciences, Inc.

Nasdaq:CSTL

CSTL Rankings

#2700 Ranked by Market Cap
N/A Ranked by Dividends

CSTL Stock Data

842.46M
27.11M
3.25%
95.3%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FRIENDSWOOD